Japanese journal of clinical oncology最新文献

{"title":"Public insurance costs of end-of-life care in hospice residential facilities in Japan: an exploratory comparison with palliative care units.","authors":"Tomoyo Sasahara, Toshie Ogasawara, Jun Hamano, Megumi Umeda, Yoshiyuki Kizawa","doi":"10.1093/jjco/hyag164","DOIUrl":"https://doi.org/10.1093/jjco/hyag164","url":null,"abstract":"<p><p>Expanding non-hospital end-of-life care and clarifying associated cost structures remain major challenges in Japan. This exploratory study examined public insurance costs for patients with cancer receiving end-of-life care in hospice residential facilities (HRFs). Retrospective data and supplementary estimations for eight patients showed that the mean daily costs were JPY 32635 during the month before death and JPY 38642 during the month of death. In comparison, the national reimbursement rates for palliative care units are JPY 51350 per day for Days 1-30 and JPY 45820 per day for Days 31-60. These findings suggest that public insurance expenditures in HRFs may be lower than the benchmark reimbursement level for palliative care units. However, comparisons should be interpreted cautiously because HRFs rely on multiple home-visit services and exclude non-medical expenses, including housing and utility costs.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's reply to 'modern axillary de-escalation requires modern nodal staging'.","authors":"Takeshi Murata, Tadahiko Shien","doi":"10.1093/jjco/hyag159","DOIUrl":"https://doi.org/10.1093/jjco/hyag159","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting the surgical implications of postoperative STAS assessment in lung adenocarcinoma.","authors":"Haifeng Hu, Zhibo Yu, Zhongjun Zhang, Weicheng Yang","doi":"10.1093/jjco/hyag161","DOIUrl":"https://doi.org/10.1093/jjco/hyag161","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical perspectives on mitochondria in cancer.","authors":"Hiroko Watanabe, Yosuke Togashi","doi":"10.1093/jjco/hyag160","DOIUrl":"https://doi.org/10.1093/jjco/hyag160","url":null,"abstract":"<p><p>Mitochondria have emerged as key determinants of cancer development and therapeutic response, extending their role beyond cellular energy production. Alterations in mitochondrial metabolism, mitochondrial DNA (mtDNA), dynamics, and quality control can support tumor growth and adaptation to the tumor microenvironment, while mitochondrial fitness also shapes the function and persistence of antitumor immune cells. Thus, mitochondrial biology represents a dynamic interface between tumor cells and the immune microenvironment. This review focuses on translating mitochondrial biology into clinical cancer applications in addition to recent advances in mitochondrial research. We evaluate mitochondrial alterations and mtDNA as diagnostic, prognostic, and predictive biomarkers, alongside strategies to selectively exploit cancer mitochondrial vulnerabilities while boosting antitumor immunity. We address key hurdles in therapeutic selectivity and discuss future perspectives for integrating mitochondrial targeting into precision oncology.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modern axillary de-escalation requires modern nodal staging.","authors":"Wiebren A A Tjalma","doi":"10.1093/jjco/hyag157","DOIUrl":"https://doi.org/10.1093/jjco/hyag157","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytoreductive surgery for malignant peritoneal mesothelioma: importance of patient selection using diagnostic laparoscopy.","authors":"Akiyoshi Mizumoto, Nobuyuki Takao, Toru Imagami, Atsushi Hirata, Yasumitsu Oe, Takashi Matsunaga, Akira Sogawa, Byonggu An, Takeshi Togawa","doi":"10.1093/jjco/hyag166","DOIUrl":"https://doi.org/10.1093/jjco/hyag166","url":null,"abstract":"<p><strong>Background: </strong>Malignant peritoneal mesothelioma (MPM) is a rare malignancy for which cytoreductive surgery (CRS), usually combined with hyperthermic intraperitoneal chemotherapy, is considered in selected patients. However, resectability may be difficult to assess preoperatively, particularly when small-bowel or mesenteric involvement is suspected. The primary aim was to describe CRS outcomes, with a secondary exploratory aim of evaluating the role of diagnostic laparoscopy in patient selection.</p><p><strong>Methods: </strong>We retrospectively reviewed 45 consecutive patients with MPM who underwent surgical assessment of resectability between 2008 and 2025. Surgical outcomes after CRS and overall survival were evaluated. Patient selection according to the initial surgical assessment strategy and reasons for non-CRS were also assessed descriptively.</p><p><strong>Results: </strong>Eighteen patients underwent upfront exploratory laparotomy and 27 underwent diagnostic laparoscopy. CRS was ultimately performed in 22 patients: 13 after upfront laparotomy and 9 after diagnostic laparoscopy. Among patients undergoing CRS, complete or near-complete cytoreduction (CC-0/1) was achieved in 5 of 13 patients (38%) in the upfront laparotomy group and in all 9 patients (100%) selected for CRS after diagnostic laparoscopy. Among the 18 patients who did not proceed to CRS after diagnostic laparoscopy, 17 had extensive small-bowel and/or mesenteric involvement. The 5-year overall survival after CRS was 52%, and was 58% in patients with CC-0/1 cytoreduction.</p><p><strong>Conclusions: </strong>CRS was associated with encouraging long-term survival in carefully selected patients with MPM. Diagnostic laparoscopy may facilitate assessment of resectability, particularly when small-bowel or mesenteric involvement is uncertain, and may help avoid non-therapeutic laparotomy in selected patients.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's reply to 'interpreting the surgical implications of postoperative STAS assessment in lung adenocarcinoma'.","authors":"Asato Hashinokuchi, Masafumi Yamaguchi","doi":"10.1093/jjco/hyag162","DOIUrl":"https://doi.org/10.1093/jjco/hyag162","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-onset chemotherapy-induced neutropenia and ascites control in patients with severe peritoneal metastasis of gastric cancer: a post hoc analysis of the JCOG1108/WJOG7312G trial.","authors":"Kunihiro Tsuji, Akifumi Notsu, Kensei Yamaguchi, Narikazu Boku, Hiroki Hara, Tomohiro Nishina, Masahiro Tsuda, Kohei Shitara, Katsunori Shinozaki, Hisato Kawakami, Kentaro Yamazaki, Hironaka Shuichi, Kei Muro, Takaki Yoshikawa, Takako Eguchi Nakajima","doi":"10.1093/jjco/hyag155","DOIUrl":"https://doi.org/10.1093/jjco/hyag155","url":null,"abstract":"<p><strong>Objective: </strong>Early-onset chemotherapy-induced neutropenia (EON) is reportedly associated with favorable patient outcomes in various cancers. However, the clinical significance of EON in patients with severe peritoneal metastasis remains unclear. We investigated the associations between EON and clinical outcomes in gastric cancer patients with severe peritoneal metastasis enrolled in the JCOG1108/WJOG7312G trial.</p><p><strong>Methods: </strong>Among 101 enrolled patients, 95 who survived ≥4 weeks were analyzed using a 4-week landmark approach. EON was defined as the lowest neutrophil count <2000/mm3 within 4 weeks after treatment initiation. We compared overall survival (OS), progression-free survival (PFS), ascites control, oral intake, and safety between the patients with and without EON.</p><p><strong>Results: </strong>Thirty-five patients developed EON and 60 did not. Median OS was 9.8 and 5.8 months in the EON and non-EON groups, respectively [hazard ratio (HR), 0.73; 95% confidence interval (CI), 0.47-1.13; P = .15], while the median PFS was 5.8 and 3.3 months (HR, 0.91; 95% CI, 0.58-1.42; P = .67), respectively. The ascites control rate was significantly higher in the EON group compared with the non-EON group [48.5% (16/33) vs. 25.4% (15/59), P = .04]. Grade ≥ 3 neutropenia though the treatment course was significantly higher in the EON group than in the non-EON group [31.4% (11/35) vs. 11.7% (7/60), P = .03].</p><p><strong>Conclusions: </strong>EON was associated with improved ascites control but not with statistically significant differences in OS or PFS. EON may represent an early clinical marker associated with ascites control in gastric cancer patients with severe peritoneal metastasis.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2025 revision of JPOS/JASCC clinical guidelines for delirium in adult patients with cancer: a summary of recommendations.","authors":"Yoshinobu Matsuda, Jun Kako, Takaaki Hasegawa, Saho Wada, Hitoshi Tanimukai, Shinichiro Inoue, Kaori Shinsato, Yusuke Kanno, Tetsuro Ishida, Yuichi Kitaura, Akiharu Okamoto, Shuntaro Yasuda, Saki Harashima, Nozomu Oya, Shuji Inada, Yoshinori Saeki, Koji Sugano, Yoshihiro Yamamoto, Masafumi Yoshimura, Takatoshi Hirayama, Tetsuya Ito, Kazuyuki Niki, Yoshiaki Okamoto, Kosuke Yamanaka, Masamitsu Kobayashi, Takafumi Miyoshi, Mari Takeuchi, Ryoichi Sadahiro, Toru Okuyama","doi":"10.1093/jjco/hyag154","DOIUrl":"https://doi.org/10.1093/jjco/hyag154","url":null,"abstract":"<p><strong>Background: </strong>The Japan Psycho-Oncology Society and the Japanese Association of Supportive Care in Cancer revised the clinical practice guidelines for delirium in adult patients with cancer in 2025. In this article, we describe the guideline revision and summarize the updated recommendations.</p><p><strong>Methods: </strong>These guidelines were developed in accordance with the Minds Manual for Clinical Practice Guideline Development 2020. The multidisciplinary guideline development group formulated four new clinical questions (CQs) addressing delirium prevention (ramelteon and orexin receptor antagonists) and management (combination therapies of antipsychotics with either benzodiazepines or antihistamines). In addition, systematic reviews of 11 existing CQs were updated.</p><p><strong>Results: </strong>Multicomponent interventions were strongly recommended for delirium prevention, based on moderate-certainty evidence. Bright light therapy, antipsychotics, ramelteon, and orexin receptor antagonists were not recommended for prevention. For delirium management, antipsychotics, trazodone, the combination of antipsychotics and benzodiazepines, and opioid switching were suggested, whereas hydroxyzine, benzodiazepines alone, and the combination of antipsychotics and antihistamines were not recommended. All recommendations for delirium management were weak, with low- to very-low-certainty evidence. Background questions addressed delirium assessment tools, precipitating factors, non-pharmacological interventions, and interventions for terminally ill patients.</p><p><strong>Conclusions: </strong>These revised clinical practice guidelines can serve as a practical framework for optimizing prevention, assessment, and management of delirium in adult patients with cancer in Japan.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of cancer survivors diagnosed within the past 20 years accounts for 6%: a population-based study in Hiroshima, Japan.","authors":"Hiromi Sugiyama, Megumi Hori, Mai Utada, Takanori Honda, Tomohiro Matsuda, Chisato Nagata","doi":"10.1093/jjco/hyag151","DOIUrl":"https://doi.org/10.1093/jjco/hyag151","url":null,"abstract":"<p><p>For cancer survivorship care planning, we measured population-based 20-year prevalence in Hiroshima, Japan. Twenty-year limited-duration prevalence was calculated as the number of individuals aged 0-99 years alive on 31 December 2021 who had been diagnosed with cancer during 2002-2021. A total of 166 854 survivors of invasive cancer (6.0%) and 197 330 survivors including carcinoma in situ (7.1%) were identified. Prevalence was higher in males than females (6.3% vs. 5.7%) and increased with age. Prostate and breast cancers were most prevalent among males and females, respectively. More than half of survivors of stomach, colorectal, liver, breast, uterus, and prostate cancers had lived >5 years after diagnosis, whereas survivors of pancreatic cancer were concentrated within 3 years of diagnosis. Approximately 1 in 17 individuals had a history of cancer within the past 20 years. These findings highlight the value of prevalence for understanding population-level survivorship care needs.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}